rac-N-(1-(8-chloro-3-(4-cyanophenyl)imidazo[1,2-a]pyrazin-2-yl)ethyl)-N-(2-(ethylsulfonyl)ethyl)-2-(3-fluoro-4-(trifluoromethyl)phenyl)acetamide | 1190969-53-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: rac-N-(1-(8-chloro-3-(4-cyanophenyl)imidazo[1,2-a]pyrazin-2-yl)ethyl)-N-(2-(ethylsulfonyl)ethyl)-2-(3-fluoro-4-(trifluoromethyl)phenyl)acetamide
• 英文别名: N-[1-[8-chloro-3-(4-cyanophenyl)imidazo[1,2-a]pyrazin-2-yl]ethyl]-N-(2-ethylsulfonylethyl)-2-[3-fluoro-4-(trifluoromethyl)phenyl]acetamide
• CAS: 1190969-53-9
• 化学式: C₂₈H₂₄ClF₄N₅O₃S
• 分子量: 622.043
• InChiKey: WNDUVPYZKSJMGI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  42
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  117
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  三乙基硼 、 rac-N-(1-(8-chloro-3-(4-cyanophenyl)imidazo[1,2-a]pyrazin-2-yl)ethyl)-N-(2-(ethylsulfonyl)ethyl)-2-(3-fluoro-4-(trifluoromethyl)phenyl)acetamide 在 2-双环己基膦-2',6'-二甲氧基联苯 、 potassium phosphate 、 tris-(dibenzylideneacetone)dipalladium(0) 作用下， 以 四氢呋喃 为溶剂， 以77%的产率得到N-[1-[3-(4-cyanophenyl)-8-ethylimidazo[1,2-a]pyrazin-2-yl]ethyl]-N-(2-ethylsulfonylethyl)-2-[3-fluoro-4-(trifluoromethyl)phenyl]acetamide
  参考文献：
  名称：

  Imidazo-pyrazine derivatives as potent CXCR3 antagonists

  摘要：

  A general way of improving the potency of CXCR3 antagonists with fused hetero-bicyclic cores was identified. Optimization efforts led to the discovery of a series of imidazo-pyrazine derivatives with improved pharmacokinetic properties in addition to increased potency. The efficacy of the lead compound 21 is evaluated in a mouse lung inflammation model. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2009.07.021
• 作为产物：
  描述：

  C₂₈H₂₅F₄N₅O₄S 在 三氯氧磷 作用下， 以94%的产率得到rac-N-(1-(8-chloro-3-(4-cyanophenyl)imidazo[1,2-a]pyrazin-2-yl)ethyl)-N-(2-(ethylsulfonyl)ethyl)-2-(3-fluoro-4-(trifluoromethyl)phenyl)acetamide
  参考文献：
  名称：

  Imidazo-pyrazine derivatives as potent CXCR3 antagonists

  摘要：

  A general way of improving the potency of CXCR3 antagonists with fused hetero-bicyclic cores was identified. Optimization efforts led to the discovery of a series of imidazo-pyrazine derivatives with improved pharmacokinetic properties in addition to increased potency. The efficacy of the lead compound 21 is evaluated in a mouse lung inflammation model. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2009.07.021